Editas Medicine Hosts Conference Call to Discuss Second Quarter 2022 Results and Business Updates



CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wednesday, August 3, 2022 at 8:00 a.m. ET to provide financial results and updates from the company for the second quarter of 2022.

To access the conference call:

  • US callers should dial 1-877-407-0989 and international callers should dial +1-201-389-0921 approximately five minutes before the call starts.
  • Participants must request to be connected to the Editas Medicine Earnings conference call.

The conference call will also be webcast and accessible from the “Investors” section of Editas Medicine’s website at https://www.editasmedicine.com/. The webcast of the call will be available on the same site approximately one hour after the call ends.

About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust portfolio of treatments for people with serious illnesses all over the world. Editas Medicine aims to discover, develop, manufacture and commercialize precision, sustainable and transformative genomic medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of the Harvard and Broad Institute Cas9 patent domains and the Broad Institute Cas12a patent domain for human medicines. For the latest scientific information and presentations, please visit www.editasmedicine.com.

Media Contact:
Cristi Barnett
(617) 401-0113
[email protected]

Investor contacts:
Ron Moldaver
(617) 401-9052
[email protected]

main logo

Source link


Comments are closed.